US 12,220,434 B2
Altering the intestinal microbiome in cystic fibrosis
George A. O'Toole, Hanover, NH (US); and Juliette C. Madan, Lyme, NH (US)
Assigned to Trustees of Dartmouth College, Hanover, NH (US); and Dartmouth-Hitchcock Clinic, Lebanon, NH (US)
Filed by Trustees of Dartmouth College, Hanover, NH (US); and Dartmouth-Hitchcock Clinic, Lebanon, NH (US)
Filed on May 19, 2022, as Appl. No. 17/664,156.
Application 17/664,156 is a continuation of application No. 16/979,824, granted, now 11,351,208, previously published as PCT/US2019/024045, filed on Mar. 26, 2019.
Claims priority of provisional application 62/649,230, filed on Mar. 28, 2018.
Prior Publication US 2022/0362310 A1, Nov. 17, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/745 (2015.01); A61K 35/741 (2015.01); A61K 35/744 (2015.01); A61K 45/06 (2006.01); A61P 1/00 (2006.01); A61P 11/00 (2006.01)
CPC A61K 35/745 (2013.01) [A61K 35/741 (2013.01); A61K 35/744 (2013.01); A61K 45/06 (2013.01); A61P 1/00 (2018.01); A61P 11/00 (2018.01)] 31 Claims
 
1. A method of altering the intestinal microbiome in a patient diagnosed with cystic fibrosis, wherein the patient is 0 days to 6 months old and has a relative abundance of intestinal Bacteroides of not more than 20%, a relative abundance of intestinal Bifidobacterium of not more than 20%, or both, the method comprising:
administering at least one of Bifidobacterium or Bacteroides to the patient's gastrointestinal tract and allowing the Bifidobacterium or Bacteroides to alter the intestinal microbiome, wherein altering the intestinal microbiome reduces the risk of, reduces the severity of, or delays the onset of a pulmonary infection or pulmonary exacerbation.